National Heart, Lung, and Blood Institute; Notice of Closed Meetings, 35637-35638 [2013-13996]

Download as PDF Federal Register / Vol. 78, No. 114 / Thursday, June 13, 2013 / Notices Ron A. Otten, Director, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. [FR Doc. 2013–14037 Filed 6–12–13; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Prospective Grant of Exclusive License: Modulation of Poliovirus Replicative Fitness by Deoptimization of Synonymous Codons Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice. AGENCY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i) that the Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS), is considering granting an exclusive license, in the field of use of vaccine targets for treatment or prevention of diseases in human health and in animal health, to practice the inventions listed in the patent applications referred to below to Codagenix Inc., having a place of business in Stony Brook, New York. The patent rights in these inventions have been assigned to the government of the United States of America. The patent applications(s) to be licensed are: SUMMARY: tkelley on DSK3SPTVN1PROD with NOTICES US Provisional Application 60/617,545, filed 10/8/2004, entitled ‘‘Modulation of Poliovirus Replicative Fitness by Deoptimization of Synonymous Codons’’; PCT Application PCT/US05/036241, filed 10/ 7/2005, entitled ‘‘Modulation of Poliovirus Replicative Fitness by Deoptimization of Synonymous Codons’’; US National Stage Application 11/576,941, filed 11/19/2007, entitled ‘‘Modulation of Poliovirus Replicative Fitness by Deoptimization of Synonymous Codons’’; and all related continuing and foreign patents/patent applications for the technology family. CDC Technology ID No. I–025–04. Status: Pending. Priority Date(s): 10/8/2004. If granted, the licensee will pay CDC royalties in accordance with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. Technology Infections by intracellular pathogens such as viruses, bacteria and parasites, are cleared in most cases after activation of specific T cellular immune responses VerDate Mar<15>2010 16:58 Jun 12, 2013 Jkt 229001 that recognize foreign antigens and eliminate infected cells. Vaccines against those infectious organisms have been traditionally developed by administration of whole live attenuated or inactivated microorganisms. Although research has been performed using subunit vaccines, the levels of cellular immunity induced are usually low and not capable of eliciting complete protection against diseases caused by intracellular microbes. However, CDC inventors discovered that replacement of one or more natural (or native) codons in a pathogen with synonymous non-preferred codons can decrease the replicative fitness of the pathogen, thereby attenuating the pathogen. The non-preferred synonymous codon(s) encode the same amino acid as the native codon(s), but have nonetheless been found to reduce a pathogen’s replicative fitness. This invention teaches compositions and methods that can be used to develop attenuated vaccines having well-defined levels of replicative fitness and enhanced genetic stabilities. Only written comments and/or applications for a license which are received by CDC on or before July 15, 2013 will be considered. 35637 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Environmental Health Sciences; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Institute of Environmental Health Sciences Special Emphasis Panel, July 15, 2013, 8:00 a.m. to July 15, 2013, 5:00 p.m., National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Research Triangle Park, NC, 27709 which was published in the Federal Register on May 29, 2013, 2013–12635. The meeting notice is amended to change the date of the meeting from July 15, 2013 to July 16, 2013. The meeting is closed to the public. Dated: June 7, 2013. Carolyn Baum, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–13997 Filed 6–12–13; 8:45 am] BILLING CODE 4140–01–P DATES: Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the planned license should be directed to Donald Prather, J.D., Ph.D., Technology Licensing and Marketing Specialist, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K–79, Atlanta, GA 30341, Telephone: (770) 488–8612; Facsimile: (770) 488–8615; Email: dmprather@cdc.gov. ADDRESSES: SUPPLEMENTARY INFORMATION: Applications for a license filed in response to this notice will be treated as objections to the giving of the planned license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: June 7, 2013. J. Ronald Campbell, Director, Division of Executive Secretariat, Centers for Disease Control and Prevention. [FR Doc. 2013–14036 Filed 6–12–13; 8:45 am] BILLING CODE 4163–18–P PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Functional Assays to Screen Genomic Hits. Date: July 2, 2013. Time: 8:30 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: YingYing Li-Smerin, MD, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge E:\FR\FM\13JNN1.SGM 13JNN1 35638 Federal Register / Vol. 78, No. 114 / Thursday, June 13, 2013 / Notices Drive, Room 7184, Bethesda, MD 20892– 7924, 301–435–0277, lismerin@nhlbi.nih.gov. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Clinical Trials SEP Review. Date: July 3, 2013. Time: 11:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Room 7188, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Chang Sook Kim, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7188, Bethesda, MD 20892–7924, 301–435– 0287, carolko@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: June 7, 2013. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–13996 Filed 6–12–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Coast Guard [Docket No. USCG–2013–0225] Certificate of Alternative Compliance for the NOAA Research Vessel FSV–6 RUBEN LASKER, 9664988 Coast Guard, DHS. ACTION: Notice. tkelley on DSK3SPTVN1PROD with NOTICES AGENCY: SUMMARY: The Coast Guard announces that a Certificate of Alternative Compliance was issued for the NOAA research vessel FSV–6 RUBEN LASKER as required by 33 U.S.C. 1605(c) and 33 CFR 81.18. DATES: The Certificate of Alternative Compliance was issued on December 20, 2012. ADDRESSES: The docket for this notice is available for inspection or copying at the Docket Management Facility (M–30), U.S. Department of Transportation, West Building Ground Floor, Room W12–140, 1200 New Jersey Avenue SE., Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. You may also find this docket on the Internet by going to https://www.regulations.gov, inserting USCG–2013–0225 in the ‘‘SEARCH’’ box, and then clicking ‘‘Search.’’ FOR FURTHER INFORMATION CONTACT: If you have questions on this notice, call VerDate Mar<15>2010 16:58 Jun 12, 2013 Jkt 229001 LT Steven Melvin, District Nine, Prevention Branch, U.S. Coast Guard, telephone 216–902–6343. If you have questions on viewing or submitting material to the docket, call Barbara Hairston, Program Manager, Docket Operations, telephone 202–366–9826. SUPPLEMENTARY INFORMATION: Background and Purpose A Certificate of Alternative Compliance, as allowed for under 33 U.S.C. 1605(c) and 33 CFR 81.18, has been issued for the NOAA research vessel FSV–6 RUBEN LASKER. The vessel’s primary purpose is to conduct oceanographic research around the world. The unique design of the vessel did not lend itself to full compliance with Annex I of the Inland Rules Act. The Commandant, U.S. Coast Guard, certifies that full compliance with the Inland Rules Act would interfere with the special functions/intent of the vessel and would not significantly enhance the safety of the vessel’s operation. Placing the special purpose fishing and stern light in the required position would interfere with the vessel’s science and boat/davit operations. The Certificate of Alternative Compliance authorizes the NOAA research vessel FSV–6 RUBEN LASKER to deviate from the requirements set forth in Annex I of the Inland Rules Act by placing its special purpose fishing lights on the main masthead at FR50 and the stern light at the stern at FR100. This notice is issued under authority of 33 U.S.C. 1605(c), and 33 CFR 81.18. Dated: May 10, 2013. S.E. Anderson, Commander, U.S. Coast Guard, Acting Chief, Prevention Division, By Direction of the Commander, Ninth Coast Guard District. [FR Doc. 2013–14080 Filed 6–12–13; 8:45 am] BILLING CODE 9110–04–P DEPARTMENT OF HOMELAND SECURITY Coast Guard [Docket No. USCG–2013–0406] Certificate of Alternative Compliance for the M/V CHARLEVOIX, 225736 Coast Guard, DHS. Notice. AGENCY: ACTION: The Coast Guard announces that a Certificate of Alternative Compliance was issued for the passenger vessel ferry CHARLEVOIX as required by 33 U.S.C. 1605(c) and 33 CFR 81.18. SUMMARY: PO 00000 Frm 00037 Fmt 4703 Sfmt 9990 The Certificate of Alternative Compliance was issued on May 10, 2013. DATES: The docket for this notice is available for inspection or copying at the Docket Management Facility (M–30), U.S. Department of Transportation, West Building Ground Floor, Room W12–140, 1200 New Jersey Avenue SE., Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. You may also find this docket on the Internet by going to https://www.regulations.gov, inserting USCG–2013–0406 in the ‘‘SEARCH’’ box, and then clicking ‘‘Search.’’ FOR FURTHER INFORMATION CONTACT: If you have questions on this notice, call LT Steven Melvin, District Nine, Prevention Branch, U.S. Coast Guard, telephone 216–902–6343. If you have questions on viewing or submitting material to the docket, call Renee V. Wright, Program Manager, Docket Operations, telephone 202–366–9826. SUPPLEMENTARY INFORMATION: ADDRESSES: Background and Purpose A Certificate of Alternative Compliance, as allowed for under 33 U.S.C. 1605 (c) and 33 CFR 81.18, has been issued for the M/V CHARLEVOIX. The vessel’s primary purpose is a cable guided passenger car ferry that operates on the South Arm of Lake Superior in Charlevoix, Michigan. The unique design of the vessel did not lend itself to full compliance with Annex I of the Inland Rules Act. The Commandant, U.S. Coast Guard, certifies that full compliance with the Inland Rules Act would interfere with the special functions/intent of the vessel and would not significantly enhance the safety of the vessel’s operation. Placing the single masthead and stern lights on this cable guided passenger and vehicle ferry would obstruct the vehicle deck. The Certificate of Alternative Compliance authorizes the M/V CHARLEVOIX to deviate from the requirements set forth in Annex I of the Inland Rules Act, by installing two Masthead lights for each direction of travel as near as practical to the vessel centerline and two sets of stern lights for each direction of travel as the aft and forward end of the deckhouse. This notice is issued under authority of 33 U.S.C. 1605(c), and 33 CFR 81.18. Dated: May 24, 2013. S. E. Anderson, Commander, U.S. Coast Guard, Acting Chief, Prevention Division by Direction of the Commander, Ninth Coast Guard District. [FR Doc. 2013–14085 Filed 6–12–13; 8:45 am] BILLING CODE 9110–04–P E:\FR\FM\13JNN1.SGM 13JNN1

Agencies

[Federal Register Volume 78, Number 114 (Thursday, June 13, 2013)]
[Notices]
[Pages 35637-35638]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-13996]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Heart, Lung, and Blood Institute; Notice of Closed 
Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Heart, Lung, and Blood Institute 
Special Emphasis Panel; Functional Assays to Screen Genomic Hits.
    Date: July 2, 2013.
    Time: 8:30 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 
Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: YingYing Li-Smerin, MD, Ph.D., Scientific Review 
Officer, Office of Scientific Review/DERA, National Heart, Lung, and 
Blood Institute, 6701 Rockledge

[[Page 35638]]

Drive, Room 7184, Bethesda, MD 20892-7924, 301-435-0277, 
lismerin@nhlbi.nih.gov.

    Name of Committee: National Heart, Lung, and Blood Institute 
Special Emphasis Panel; Clinical Trials SEP Review.
    Date: July 3, 2013.
    Time: 11:00 a.m. to 1:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, Room 
7188, Bethesda, MD 20892, (Telephone Conference Call).
    Contact Person: Chang Sook Kim, Ph.D., Scientific Review 
Officer, Office of Scientific Review/DERA, National Heart, Lung, and 
Blood Institute, 6701 Rockledge Drive, Room 7188, Bethesda, MD 
20892-7924, 301-435-0287, carolko@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

    Dated: June 7, 2013.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-13996 Filed 6-12-13; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.